Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Aharona Glatman-Freedman,Michal Bromberg,Yael Hershkovitz,Hanna Sefty,Zalman Kaufman,Rita Dichtiar,Lital Keinan-Boker +6 more
TLDR
The more pronounced VE decline coincided with rapid increase in Omicron variant activity, and rate reduction of breakthrough complications remained moderate to high throughout the evaluation.Abstract:
We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%–97.5%) for persons 16–59 years of age and 93.1% (95% CI 91.8%–94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16–59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2–3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%–84.2%) and 61.3% (52.5%–68.4%) for persons 16–59 years and >60 years, respectively. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.read more
Citations
More filters
Journal ArticleDOI
Expert review on global real-world vaccine effectiveness against SARS-CoV-2
TL;DR: In this paper , the authors reviewed 79 studies in the International Vaccine Access Center (IVAC) VIEW-hub platform on vaccine effectiveness after primary immunizations with two-dose schedules and reported that the most studied COVID-19 vaccines provide consistently high (>90%) protection against serious clinical outcomes like hospitalizations and deaths, regardless of variant.
Journal ArticleDOI
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
Nana Wu,Keven Joyal-Desmarais,Paula A B Ribeiro,Ariany Marques Vieira,Jovana Stojanovic,Comfort Titilope Sanuade,Doro Yip,Simon L. Bacon +7 more
Journal ArticleDOI
Preliminary Study of the Protectiveness of Vaccination Against the COVID-19 in the Outbreak of VOC Omicron BA.2 — Jilin City, Jilin Province, China, March 3–April 12, 2022
Xuebin Fan,Shan Lu,Luping Bai,Haican Liu,J. Fu,Xiaoxun Jin,Yulong He,Jinxing Lu,Xiao-Ping Dong +8 more
TL;DR: The incidences of each type of COVID-19 in the population who were fully vaccinated or booster vaccinated in Jilin City were significantly lower than those who were unvaccinated and/or partially vaccinated.
Journal ArticleDOI
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
TL;DR: In this paper , the long-term vaccine effectiveness of COVID-19 vaccines against SARS-CoV-2 infections, hospitalisations, and mortality was evaluated using three-level meta-analytic models.
Journal ArticleDOI
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination
Hope R. Lapointe,Francis Mwimanzi,Peter K. Cheung,Yu-Ying Sang,Fatimah Hassoon Yaseen,Rebecca Kalikawe,Sneha Datwani,Rachel Waterworth,Gisele Umviligihozo,Siobhan Ennis,L. Young,Winnie Dong,Don Kirkby,L. Burns,Victor C. M. Leung,D. Holmes,Mari L. DeMarco,Janet Simons,Nancy Matic,Julio S. G. Montaner,Chanson J. Brumme,Natalie Prystajecky,Masahiro Niikura,Christopher F. Lowe,Marc G. Romney,Mark A. Brockman,Zabrina L. Brumme +26 more
TL;DR: Though vaccines clearly protect against severe disease, results highlight the continued importance of maintaining additional protective measures to counteract the immune-evasive Omicron variant, particularly as vaccine-induced immune responses naturally decline over time.
References
More filters
Journal ArticleDOI
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
Yinon M. Bar-On,Yair Goldberg,Micha Mandel,Omri Bodenheimer,Laurence Freedman,Nir Kalkstein,Barak Mizrahi,Sharon Alroy-Preis,Nachman Ash,Ron Milo,Amit Huppert +10 more
TL;DR: In this paper, the authors investigated the effect of the booster dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rates of severe illness.
Journal ArticleDOI
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Noam Barda,Noa Dagan,Cyrille J. Cohen,Miguel A. Hernán,Marc Lipsitch,Isaac S. Kohane,Ben Y. Reis,Ran D Balicer,Ran D Balicer,Ran D Balicer +9 more
TL;DR: In this article, the authors used the data repositories of Clalit Health Services to evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes.
Journal ArticleDOI
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Nick Andrews,Julia Stowe,Freja C M Kirsebom,Samuel E. Toffa,Ruchi Sachdeva,Charlotte Gower,Mary Ramsay,Jamie Lopez Bernal +7 more
TL;DR: In this paper , the authors used a test-negative case-control design to estimate the relative effectiveness of a booster dose of BNT162b2 (Pfizer-BioNTech) compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation.
Journal ArticleDOI
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Nick Andrews,Julia Stowe,Freja C M Kirsebom,Samuel E. Toffa,Ruchira Sachdeva,Charlotte Gower,Mary Ramsay,Jamie Lopez Bernal +7 more
TL;DR: In this article , the authors used a test-negative case-control design to estimate the relative effectiveness of a booster dose of BNT162b2 compared to only a two-dose primary course (at least 175 days after the second dose) or unvaccinated individuals from 13 September 2021 to 5 December 2021, when Delta variant was dominant in circulation.